J Rheum Dis.  2017 Jun;24(3):125-126. 10.4078/jrd.2017.24.3.125.

Is Urinary Tumor Necrosis Factor-like Weak Inducer of Apoptosis a Biomarker of Lupus Nephritis?

Affiliations
  • 1Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea. min6403@catholic.ac.kr

Abstract

No abstract available.


MeSH Terms

Apoptosis*
Lupus Nephritis*
Necrosis*

Reference

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999; 10:413–24.
Article
2. Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol. 2015; 11:46–61.
Article
3. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012; 27:3248–54.
Article
4. Li Y, Tucci M, Narain S, Barnes EV, Sobel ES, Segal MS, et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev. 2006; 5:383–8.
Article
5. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 2004; 50:1709–20.
Article
6. Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis. 2013; 5:210–33.
Article
7. Misra R, Gupta R. Biomarkers in lupus nephritis. Int J Rheum Dis. 2015; 18:219–32.
Article
8. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002; 27:19–26.
Article
9. Wajant H. The TWEAK-Fn14 system as a potential drug target. Br J Pharmacol. 2013; 170:748–64.
Article
10. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008; 7:411–25.
Article
11. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005; 123:931–44.
Article
12. Baxter FO, Came PJ, Abell K, Kedjouar B, Huth M, Rajewsky K, et al. IKKbeta/2 induces TWEAK and apoptosis in mam-mary epithelial cells. Development. 2006; 133:3485–94.
13. Xu WD, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res. 2016; 64:44–50.
Article
14. Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol. 2015; 26:1053–70.
Article
15. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol. 2006; 176:1889–98.
Article
16. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun. 2006; 27:242–50.
Article
17. Lee YH, Song GG. Urinary tumor necrosis factor-like weak inducer of apoptosis as a biomarker for lupus nephritis: a meta-analysis. J Rheum Dis. 2017; 24:85–92.
Article
18. Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012; 64:2687–97.
Article
Full Text Links
  • JRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr